Product Description
Debio 0432 is a small molecule with best-in-class potential that could be deployed to combat multiple tumor types. Through its potent and selective inhibition of USP1, a critical player in DNA damage repair (DDR) pathway, Debio 0432 has the potential to induce synthetic lethality in tumor types with underlying defects of DNA repair genes (such as BCRA1). ‘Synthetic lethality, a process in which alterations in at least two different genes result in cell death due to inability of repairing DNA defects, is a novel and promising cancer therapy. (Sourced from: https://www.debiopharm.com/pipeline/debio-0432/)
Mechanisms of Action: USP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Debiopharm
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|